神经精神症状与补充和替代医学的支出
Neuropsychiatric symptoms and expenditure on complementary and alternative medicine.
作者信息
Purohit Maulik P, Zafonte Ross D, Sherman Laura M, Davis Roger B, Giwerc Michelle Y, Shenton Martha E, Yeh Gloria Y
机构信息
Spaulding Rehabilitation Hospital Network, 300 First Ave, Charlestown, MA 02129
出版信息
J Clin Psychiatry. 2015 Jul;76(7):e870-6. doi: 10.4088/JCP.13m08682.
OBJECTIVE
Neuropsychiatric symptoms affect 37% of US adults. These symptoms are often refractory to standard therapies, and patients may consequently opt for complementary and alternative medicine therapies (CAM). We sought to determine the demand for CAM by those with neuropsychiatric symptoms compared to those without neuropsychiatric symptoms as measured by out-of-pocket expenditure.
METHOD
We compared CAM expenditure between US adults with and without neuropsychiatric symptoms (n = 23,393) using the 2007 National Health Interview Survey. Symptoms included depression, anxiety, insomnia, attention deficits, headaches, excessive sleepiness, and memory loss. CAM was defined per guidelines from the National Institutes of Health as mind-body therapies, biological therapies, manipulation therapies, or alternative medical systems. Expenditure on CAM by those without neuropsychiatric symptoms was compared to those with neuropsychiatric symptoms.
RESULTS
Of the adults surveyed, 37% had ≥ 1 neuropsychiatric symptom and spent $14.8 billion out-of-pocket on CAM. Those with ≥ 1 neuropsychiatric symptom were more likely than those without neuropsychiatric symptoms to spend on CAM (27.4% vs 20.3%, P < .001). Likelihood to spend on CAM increased with number of symptoms (27.2% with ≥ 3 symptoms, P < .001). After adjustment was made for confounders using logistic regression, those with ≥ 1 neuropsychiatric symptom remained more likely to spend on CAM (odds ratio [OR] = 1.34; 95% CI, 1.22-1.48), and the likelihood increased to 1.55 (95% CI, 1.34-1.79) for ≥ 3 symptoms. Anxiety (OR = 1.40 [95% CI, 1.22-1.60]) and excessive sleepiness (OR = 1.36 [95% CI, 1.21-1.54]) were the most closely associated with CAM expenditure.
CONCLUSIONS
Those with ≥ 1 neuropsychiatric symptom had disproportionately higher demand for CAM than those without symptoms. Research regarding safety, efficacy, and cost-effectiveness of CAM is limited; therefore, future research should evaluate these issues given the tremendous demand for these treatments.
目的
神经精神症状影响着37%的美国成年人。这些症状往往对标准疗法无效,因此患者可能会选择补充和替代医学疗法(CAM)。我们试图通过自付费用来确定有神经精神症状者与无神经精神症状者对CAM的需求。
方法
我们使用2007年美国国家健康访谈调查,比较了有和没有神经精神症状的美国成年人(n = 23,393)的CAM支出。症状包括抑郁、焦虑、失眠、注意力缺陷、头痛、过度嗜睡和记忆力减退。根据美国国立卫生研究院的指南,CAM被定义为身心疗法、生物疗法、手法治疗或替代医学系统。比较了无神经精神症状者与有神经精神症状者在CAM上的支出。
结果
在接受调查的成年人中,37%有≥1种神经精神症状,自付148亿美元用于CAM。有≥1种神经精神症状的人比没有神经精神症状的人更有可能在CAM上支出(27.4%对20.3%,P <.001)。在CAM上支出的可能性随着症状数量的增加而增加(≥3种症状的人为27.2%,P <.001)。使用逻辑回归对混杂因素进行调整后,有≥1种神经精神症状的人在CAM上支出的可能性仍然更高(优势比[OR]=1.34;95%可信区间,1.22 - 1.48),对于≥3种症状,可能性增加到1.55(95%可信区间,1.34 - 1.79)。焦虑(OR = 1.40 [95%可信区间,1.22 - 1.60])和过度嗜睡(OR = 1.36 [95%可信区间,1.21 - 1.54])与CAM支出关联最为密切。
结论
有≥1种神经精神症状的人对CAM的需求比无症状者高得多。关于CAM的安全性、有效性和成本效益的研究有限;因此,鉴于对这些治疗的巨大需求,未来的研究应该评估这些问题。
相似文献
J Clin Psychiatry. 2015-7
J Clin Psychiatry. 2015-7
Altern Ther Health Med. 2012
J Clin Psychiatry. 2013-6
J Cancer Surviv. 2016-10
引用本文的文献
World J Pediatr. 2019-12
Dialogues Clin Neurosci. 2018-9
Molecules. 2017-4-11
本文引用的文献
J Clin Psychiatry. 2013-6
Prev Chronic Dis. 2012-3-22
Lancet Neurol. 2012-1
J Sleep Res. 2011-12-12
Cephalalgia. 2011-7-29